Table 3 Summary of multivariable assessments for overall survival.

From: Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience

Parameter

Hazard Ratio (95% CI)

p-value

R-ISS

II vs I

3.71 (0.85, 16.13)

0.08

III vs I

6.95 (1.21, 39.90)

0.030

Unknown vs I

4.53 (0.89, 23.10)

0.07

Prior MRD/Response

Negative/≥VGPR vs. Other

0.43 (0.18, 1.04)

0.06

Del17

Present vs Absent

2.33 (1.13, 4.82)

0.023

Not done vs Absent

0.45 (0.06, 3.58)

0.45

Number of additional copies of 1q + 

> 1 vs 1

1.88 (0.93, 3.83)

0.08

t(4;14)

Present vs Absent

3.00 (1.02, 8.87)

0.047

Not done vs Absent

2.16 (0.73, 6.41)

0.16

t(14;16)

Present vs Absent

2.82 (0.80, 9.97)

0.11

Not done vs Absent

0.47 (0.14, 1.54)

0.21

Best MRD/responsea

Negative/≥VGPR vs. Other

0.29 (0.15, 0.56)

< 0.001

Maintenance therapya

Lenalidomde vs. Other

0.67 (0.33, 1.36)

0.27

  1. CI confidence interval, MRD Minimal residual disease, ref reference group, R-ISS Revised International Staging System, VGPR very good partial response.
  2. aIncluded in the model as a time-dependent covariate.
Back to article page